Taris gets $12.5 million for bladder drug delivery candidate; Pfizer joins BIND for nanoparticle delivery;

> Taris Biomedical snagged $12.5 million in funding for its LiRIS candidate that delivers drugs directly to the bladder. 

> Pfizer ($PFE) inked a deal with BIND Biosciences, a Robert Langer venture, to get a piece of the nanoparticle drug delivery market. More

> Eli Lilly ($LLY) is pumping money into its facility devoted to filling insulin cartridges, investing $180 million in the plant, adding to the $140 million added last year. Story

> Researchers at the Johns Hopkins University School of Medicine have found that sublingual delivery of allergens could be effective for patients with allergic rhinitis. Article

> The FDA approved Tris Pharma's extended-release option for Karbinal, a drug to treat allergic rhinitis, in oral delivery form. Release

> Oramed ($ORMP) snagged Japanese approval of its patent on the oral delivery of proteins. Release

> A compound, cyclodextrin, used as an ingredient in other drugs is undergoing tests to determine whether it will improve other treatments by helping with the delivery of cholesterol to the brain. More

Suggested Articles

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.

Alexion's 100 mg/ml Ultomiris formulation is expected to slash infusion times by about 60% and bodes well for a planned subcutaneous version, too.